TP53 and small cell lung carcinoma: Consistent with known key characteristics of SCLC, NGS revealed mutations (primarily missense and truncating mutations) with the rarer splice and in-frame mutations in TP53 in 24 out of 26 (92%) clinical samples and truncating splice mutations, structural variants, and deep deletions in RB1 in 21 out of 26 (81%) clinical samples (Fig. 2a).